MedTrace Logo

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

NCT00346879 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2016-02-23

No results posted yet for this study

Summary

This is a prospective open-label study comparing two dosing regimens of fondaparinux, which is used to prevent deep vein thrombosis, in morbidly obese volunteers.

Conditions

  • Morbid Obesity

Interventions

DRUG

fondaparinux

Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux

Sponsors & Collaborators

  • American Society for Bariatric Surgery

    collaborator OTHER

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Samer Mattar, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346879 on ClinicalTrials.gov